ATE475416T1 - Fettalkohole und fettsäureester zur behandlung von entzündungen - Google Patents

Fettalkohole und fettsäureester zur behandlung von entzündungen

Info

Publication number
ATE475416T1
ATE475416T1 AT02724588T AT02724588T ATE475416T1 AT E475416 T1 ATE475416 T1 AT E475416T1 AT 02724588 T AT02724588 T AT 02724588T AT 02724588 T AT02724588 T AT 02724588T AT E475416 T1 ATE475416 T1 AT E475416T1
Authority
AT
Austria
Prior art keywords
sub
fatty acid
inflammation
treatment
acid esters
Prior art date
Application number
AT02724588T
Other languages
English (en)
Inventor
Irun Cohen
Meir Shinitzky
Raanan Margalit
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE475416T1 publication Critical patent/ATE475416T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02724588T 2001-04-11 2002-04-11 Fettalkohole und fettsäureester zur behandlung von entzündungen ATE475416T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL14253501A IL142535A0 (en) 2001-04-11 2001-04-11 Pharmaceutical compositions for the treatment of inflammation
PCT/IL2002/000294 WO2002083122A1 (en) 2001-04-11 2002-04-11 Fatty alcohols and fatty acid esters useful for treatment of inflammation

Publications (1)

Publication Number Publication Date
ATE475416T1 true ATE475416T1 (de) 2010-08-15

Family

ID=11075312

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02724588T ATE475416T1 (de) 2001-04-11 2002-04-11 Fettalkohole und fettsäureester zur behandlung von entzündungen

Country Status (17)

Country Link
US (1) US20060183797A1 (de)
EP (1) EP1385500B1 (de)
JP (1) JP2004525180A (de)
KR (1) KR20030096312A (de)
CN (1) CN100352433C (de)
AT (1) ATE475416T1 (de)
AU (1) AU2002255241B2 (de)
CA (1) CA2442953A1 (de)
DE (1) DE60237148D1 (de)
HU (1) HUP0303881A3 (de)
IL (1) IL142535A0 (de)
MX (1) MXPA03009341A (de)
NO (1) NO20034558L (de)
NZ (1) NZ528784A (de)
PL (1) PL366586A1 (de)
WO (1) WO2002083122A1 (de)
ZA (1) ZA200307783B (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
EA007322B1 (ru) 2001-04-18 2006-08-25 Прометик Байосайенсиз, Инк. Жирные кислоты со средней длиной цепи, глицериды и аналоги как факторы, способствующие выживанию и активации нейтрофилов
JP4578235B2 (ja) 2002-05-13 2010-11-10 アレクシス・アクチボラゲット 自己免疫状態およびｎａｄｐｈオキシダーゼ欠損
RU2337093C2 (ru) * 2002-10-10 2008-10-27 Йеда Рисерч Энд Дивелопмент Ко.Лтд. Основные эфиры жирных кислот и их применение в качестве противовоспалительных или иммуномодулирующих средств
WO2004069237A1 (en) 2003-02-07 2004-08-19 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
US7612111B2 (en) * 2003-03-20 2009-11-03 Imagenetix, Inc. Esterified fatty acid composition
US20050158329A1 (en) 2004-01-21 2005-07-21 Ghosh Swapan K. Novel phytol derived immunoadjuvants and their use in vaccine formulations
WO2005112912A1 (en) * 2004-04-24 2005-12-01 Sang-Hee Kim Immunomoduating agent, anti-cancer agent and health food containing monoacetyldiacylglycerol derivatives
JP4954450B2 (ja) * 2004-06-14 2012-06-13 ビーエーエスエフ ビューティ ケア ソリューションズ フランス エスエーエス 弾性繊維形成の不全、欠損又は無秩序による病状に対処するための、リシルオキシダーゼのアイソフォームの活性の誘導
JP5337479B2 (ja) 2005-05-04 2013-11-06 プロノヴァ・バイオファーマ・ノルゲ・アーエス 新規化合物
JP5046926B2 (ja) * 2005-05-16 2012-10-10 日本水産株式会社 炎症性疾患予防又は治療剤
US7294739B1 (en) 2006-11-06 2007-11-13 Teva Pharmacaetical Industries Ltd. Basic amine esters or oleic acid and their use as anti-inflammatory or immunobodulatory agents
KR100787765B1 (ko) * 2006-11-07 2007-12-24 고려대학교 산학협력단 팔미트산을 포함하는 알츠하이머병의 예방 또는 치료용조성물
WO2008093772A1 (ja) * 2007-01-31 2008-08-07 Hisamitsu Pharmaceutical Co., Inc. 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
WO2008106091A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Use of long-chain alcohol derivatives for the treatment of alopecia areata
EP2114155A4 (de) 2007-02-26 2014-04-16 Yeda Res & Dev Enantiomere aus amino-phenyl-essigsäure-octadez-9-(z)-enylester, ihre salze und anwendungen davon
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
WO2008117062A1 (en) 2007-03-28 2008-10-02 Aker Biomarine Asa Bioeffective krill oil compositions
RU2519215C2 (ru) * 2007-11-02 2014-06-10 Прометик Байосайенсиз Инк. Жирные кислоты и глицериды со средней длиной цепи в качестве нефропротективных средств
WO2010028336A2 (en) * 2008-09-08 2010-03-11 President And Fellows Of Harvard College Fatty acid c16:1n7-palmitoleate a lipokine and biomarker for metabolic status
US8372812B2 (en) 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
EP2272383A1 (de) * 2009-06-22 2011-01-12 SBAE Industries NV Zusammensetzung, die Omega-7- und/oder Omega-4-Fettsäuren enthält
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
EP3064218B1 (de) 2013-10-31 2019-06-19 Hisamitsu Pharmaceutical Co., Inc. Adjuvantienzusammensetzung
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
KR102152850B1 (ko) * 2014-03-28 2020-09-07 주식회사 엘지생활건강 글리세린 지방산 유도체의 용도
AU2016217566B2 (en) 2015-02-11 2019-02-14 Aker Biomarine Human Ingredients As Lipid compositions
KR20170118125A (ko) 2015-02-11 2017-10-24 에이커 바이오마린 앤탁틱 에이에스 지질 추출 공정
AU2016219974A1 (en) * 2015-02-18 2017-09-07 Tersus Life Sciences, LLC Methods for improving joint function
SG11201810580PA (en) * 2016-06-08 2018-12-28 Sunregen Healthcare Ag Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement
KR101817552B1 (ko) * 2016-10-13 2018-01-11 주식회사 엔지켐생명과학 모노아세틸디아실글리세롤 화합물을 함유하는 간염의 예방 또는 치료용 조성물
CN108853066A (zh) * 2018-09-20 2018-11-23 成都中医药大学 链式脂肪醇在制备抗炎、镇痛药物中的用途
CN112168812B (zh) * 2019-07-02 2022-07-08 瑞微（深圳）生物科技有限公司 棕榈油酸用于制备预防或治疗炎症性疾病的组合物的用途
CN114544783B (zh) * 2020-11-20 2024-01-30 上海交通大学医学院附属瑞金医院 一种预防银屑病复发的内源性代谢物组合
CN119837845B (zh) * 2024-11-28 2025-09-26 中山大学附属第一医院广西医院 R-1，3-丁二醇在制备预防或治疗炎症性肠病药物中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US612700A (en) * 1898-10-18 Disk plow
US6458772B1 (en) * 1909-10-07 2002-10-01 Medivir Ab Prodrugs
US3592930A (en) * 1968-07-19 1971-07-13 Syntex Corp Moisture-deterioratable topical medicaments,particularly anti-inflammatory steroids,in a substantially non-aqueous fatty alcohol-propylene glycol vehicle
US4152423A (en) * 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
US4258029A (en) * 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
DE3482551D1 (de) * 1983-10-26 1990-07-26 Kanebo Ltd Proteinhaltiges emulgiermittel, dessen herstellung und dieses enthaltende emulgierte kosmetische zusammensetzung.
CH679119A5 (de) * 1988-05-13 1991-12-31 Sandoz Ag
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5194451A (en) * 1989-11-02 1993-03-16 Katz David H Systemic anti-inflammatory treatment
IE904098A1 (en) * 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
TW355153B (en) * 1996-05-21 1999-04-01 Toshiba Machine Co Ltd A method for leveling abrasive cloth and device for the same
IL163865A0 (en) * 1996-09-17 2005-12-18 Avanir Pharmaceuticals Compositions comprising a non-ionicsurfactant and n-docosanol
WO1998016216A1 (en) * 1996-10-11 1998-04-23 Scotia Holdings Plc Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
US5910306A (en) * 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US6210700B1 (en) * 1997-01-14 2001-04-03 Novartis Nutrition Ag Enhancement of transplant graft survival through nutritional immunomodulation with omega-9 fatty acid dietary supplement therapy
US6242426B1 (en) * 1997-07-25 2001-06-05 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
US6114337A (en) * 1998-11-27 2000-09-05 Pugliese; Peter T. Zwitteronic-fatty acid compounds having anti-inflammatory properties
EP0919230A1 (de) * 1997-12-01 1999-06-02 Societe Des Produits Nestle S.A. Verwendung des nmifa als Entzündungshemmer in oberflächlichem Saugetier-Gewebe
US5968524A (en) * 1997-12-23 1999-10-19 Genesis Research & Development Corp. Methods and compounds for the treatment of immunologically-mediated psoriasis
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US6118020A (en) * 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
US6271219B2 (en) * 1999-06-25 2001-08-07 Rajaram Vaidyanathan Topical formulations comprising skin penetration agents and the use thereof
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
RU2337093C2 (ru) * 2002-10-10 2008-10-27 Йеда Рисерч Энд Дивелопмент Ко.Лтд. Основные эфиры жирных кислот и их применение в качестве противовоспалительных или иммуномодулирующих средств

Also Published As

Publication number Publication date
HUP0303881A3 (en) 2009-10-28
ZA200307783B (en) 2004-10-06
IL142535A0 (en) 2002-03-10
EP1385500A1 (de) 2004-02-04
MXPA03009341A (es) 2004-02-12
US20060183797A1 (en) 2006-08-17
EP1385500B1 (de) 2010-07-28
CN1514723A (zh) 2004-07-21
HUP0303881A2 (hu) 2004-03-01
JP2004525180A (ja) 2004-08-19
WO2002083122A1 (en) 2002-10-24
NZ528784A (en) 2007-06-29
NO20034558D0 (no) 2003-10-10
CN100352433C (zh) 2007-12-05
NO20034558L (no) 2003-12-10
DE60237148D1 (de) 2010-09-09
CA2442953A1 (en) 2002-10-24
PL366586A1 (en) 2005-02-07
KR20030096312A (ko) 2003-12-24
EP1385500A4 (de) 2004-12-29
AU2002255241B2 (en) 2007-08-02

Similar Documents

Publication Publication Date Title
ATE475416T1 (de) Fettalkohole und fettsäureester zur behandlung von entzündungen
ATE478129T1 (de) Kerzenwachs auf triacylglycerin-basis
CY1111808T1 (el) Συνθεσεις εχουσες αποτελεσματα προληψης ή βελτιωσης καταστασεων ή νοσων που προκαλουνται απο εγκεφαλικη υπολειτουργια
DE60108184D1 (de) Verfahren zur Herstellung von Fettsäureestern
ATE394365T1 (de) Verfahren zur synthese von verbindungen vom ceramidtyp
DK1682226T3 (da) Lipidpræparat til forbedring af mineralabsorption
BR0112073A (pt) Combinações terapêuticas de ácidos graxos
EE200300030A (et) 4-jodofenüülaminobenshüdroksaamhapete oksügeenitud estrid
ATE422350T1 (de) Anisinsäure und glyceride enthaltende zusammensetzungen
ZA200802678B (en) Non-hydrogenated hardstock fat
ATE311201T1 (de) Testosteron-ester formulierung zur anwendung am menschen
ATE453409T1 (de) Entzündungshemmende fettalkohole und fettsäureester als antigenträger
DE59504267D1 (de) Härten von ungesättigten fetten, fettsäuren oder fettsäureestern
EP1912514A4 (de) Polyglycerolfettsäureesterprodukt und beschichtung
ATA18872000A (de) Verfahren zur herstellung von fettsäureestern niederer alkohole
FR2829491B1 (fr) Procede de preparation des hydroxy-acides gras insatures et de leurs esters, leur utilisation comme agent anti-collagenase
FR2843124B1 (fr) Procede de preparation d'acides gras polyinsatures libres et de leurs metabolites d'oxydation
PT854842E (pt) Metodos e composicoes para combater as bioincrustacoes utilizando esteres poliglicolicos de acidos gordos
WO2002049582A3 (de) Kosmetische und dermatologische lichtschutzformulierungen mit einem gehalt an benzotriazolderivaten und oberflächenaktiven zitronensäureestern
ATE256654T1 (de) Cla-ester
DE60230067D1 (de) Verwendung von estern langkettiger fettsäuren zur behandlung von autoimmunkrankheiten
DE60123564D1 (de) Verfahren zur Herstellung von Estern ungesättigter Carbonsäuren
JP2003226890A5 (de)
DK1795591T3 (da) Lipasepulver, fremgangsmåde til fremstilling af samme og anvendelse deraf
NO20031080L (no) Fettsyreanaloger for behandling av proliferative sykdommer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties